UNBELIEVABLE: Evofem biosciences | History Defined

She spent a decade trying to build better women's health care—now her startup is on the brink of failure

Evofem Biosciences CEO Saundra Pelletier has spent a decade trying to steer her startup through a litany of business challenges.

Fortune · Apr 11, 2023

‘Anything to survive’: How one leader is pushing ahead

The CEO of Evofem Biosciences is managing through a crushing debt load, Nasdaq delisting, and sweeping layoffs.

Fortune · Apr 10, 2023

U.S. women need better birth control. So why is this contraceptive company 'on life support?'

Evofem Biosciences has prescribed its nonhormonal contraceptive to more than 100,000 women, but is still on the brink of collapse.

Fortune · Apr 5, 2023

12 Health Care Stocks Moving In Friday's Intraday Session

 

Benzinga · Jun 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

 

Benzinga · Jun 2, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

 

Benzinga · May 20, 2022

Why Evofem Biosciences Shares Are Getting Hammered Today

Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading lower by 59.76% at $0.44 after the company announced the pricing of a roughly $26.6 million public offering.

Benzinga · May 20, 2022

Evofem Biosciences: Q4 Earnings Insights

Evofem Biosciences (NASDAQ:EVFM) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Mar 3, 2022